These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38595961)

  • 1. Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis.
    Chen H; Wang Z; Wang C
    Case Rep Oncol; 2024; 17(1):543-548. PubMed ID: 38595961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study.
    Li QM; Sun QC; Jian Y; He JZ; Zhu HB; Hong C; Zeng L; Li RN; Wang JR; Li Y; Chen LY; Weng X; Liu L; Dong HZ; Xiao LS; Cui H
    Discov Oncol; 2023 Jun; 14(1):105. PubMed ID: 37336826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
    Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
    J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review.
    Xie P; Guo L; Zhang B; Xu Y; Song Q; Shi H; Ye Q; Li H; Xiao Y
    Front Oncol; 2022; 12():911202. PubMed ID: 35992782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
    Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
    Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
    Wei F; Huang Q; He J; Luo L; Zeng Y
    Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
    Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
    World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report.
    Fellouah M; Auclair MH; Fortin S; Berdugo J; de Guerké L
    Gynecol Oncol Rep; 2023 Oct; 49():101235. PubMed ID: 37636497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
    Wang K; Wang H; Lv Y; Liu H; Liu J; Zhang Y
    Ann Palliat Med; 2021 Jan; 10(1):803-809. PubMed ID: 33545802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
    Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
    Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
    Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
    Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
    Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
    Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
    Deng H; Kan A; Lyu N; Mu L; Han Y; Liu L; Zhang Y; Duan Y; Liao S; Li S; Xie Q; Gao T; Li Y; Zhang Z; Zhao M
    Liver Cancer; 2020 Jun; 9(3):338-357. PubMed ID: 32647635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.